WallStSmart

DXC Technology Co (DXC)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DXC Technology Co generates 4799% more annual revenue ($12.68B vs $258.90M). DXC leads profitability with a 3.3% profit margin vs -15.5%. DXC earns a higher WallStSmart Score of 67/100 (B-).

DXC

Strong Buy

67

out of 100

Grade: B-

Growth: 4.7Profit: 5.5Value: 10.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.13

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DXCUndervalued (+89.2%)

Margin of Safety

+89.2%

Fair Value

$127.79

Current Price

$11.47

$116.32 discount

UndervaluedFair: $127.79Overvalued
ZEPPUndervalued (+48.9%)

Margin of Safety

+48.9%

Fair Value

$46.96

Current Price

$18.01

$28.95 discount

UndervaluedFair: $46.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXC4 strengths · Avg: 10.0/10
PEG RatioValuation
0.4910/10

Growing faster than its price suggests

P/E RatioValuation
5.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.6x10/10

Reasonable price relative to book value

EPS GrowthGrowth
96.8%10/10

Earnings expanding 96.8% YoY

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

DXC4 concerns · Avg: 2.5/10
Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.523/10

Elevated debt levels

Revenue GrowthGrowth
-1.0%2/10

Revenue declined 1.0%

Altman Z-ScoreHealth
1.132/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : DXC

The strongest argument for DXC centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.49 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : DXC

The primary concerns for DXC are Profit Margin, Debt/Equity, Revenue Growth. Debt-to-equity of 1.52 is elevated, increasing financial risk. Thin 3.3% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

DXC profiles as a value stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

DXC generates stronger free cash flow (372M), providing more financial flexibility.

Bottom Line

DXC scores higher overall (67/100 vs 38/100). ZEPP offers better value entry with a 48.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DXC Technology Co

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

DXC Technology is an American multinational corporation that provides business-to-business information technology services.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?